Synopsis
Synopsis
0
JDMF
0
VMF
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
2. Cp 88059
3. Cp 88059-01
4. Cp-88,059
5. Cp-88,059-01
6. Cp-88,059-1
7. Geodon
8. Ziprasidone
9. Ziprasidone Hydrochloride, Monohydrate
10. Ziprazidone
1. 122883-93-6
2. Ziprasidone Hcl
3. Geodon
4. Zeldox
5. 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one Hydrochloride
6. Ziprasidone (hydrochloride)
7. 5-[2-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one Hydrochloride
8. Ziprasidone Hydrochloride [usan]
9. Jal53626gg
10. 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one Hydrochloride
11. 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one Hydrochloride
12. Cp 88059 (hydrochloride Monohydrate)
13. 122883-93-6 (hcl)
14. 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, Monohydrochloride
15. 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1h-indol-2-one Hydrochloride
16. Cp 88059
17. Ziprasidone Hydrochloride Hydrate
18. C21h21cln4os.hcl
19. Unii-jal53626gg
20. Ziprasidone, Hcl
21. 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, Hydrochloride (1:1)
22. 2h-indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, Hydrochloride (1:1)
23. Cp-88059 Hydrochloride
24. Chembl1712
25. Mls006010221
26. Schembl122876
27. Dtxsid00153762
28. Hy-14542a
29. S1444
30. Akos015848366
31. Ac-7053
32. Ccg-220561
33. Cs-1887
34. Ks-1219
35. 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrochloride
36. Ac-26998
37. Smr002204092
38. Ziprasidone Hydrochloride Anhydrous
39. Sw199027-2
40. Z0032
41. Ziprasidone Hydrochloride Anhydrous [mi]
42. 939z277
43. A890906
44. Sr-01000759387
45. Sr-01000759387-2
46. Ziprasidone Hydrochloride Anhydrous [who-dd]
47. Q27281411
48. 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one Hcl
49. 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone Monohydrochloride
50. 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)-ethyl)-6-chloroindolin-2-one Hydrochloride
51. 5-[2-[4-(1,2-benzisothiazol-3-yl)-1 -piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol- 2-one Hydrochloride
52. 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2h-indol-2-one Hydrochloride
53. Ziprasidone Hydrochloride Solution, 1.0 Mg/ml In Methanol, Certified Reference Material, Ampule Of 1 Ml
Molecular Weight | 449.4 g/mol |
---|---|
Molecular Formula | C21H22Cl2N4OS |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 448.0891379 g/mol |
Monoisotopic Mass | 448.0891379 g/mol |
Topological Polar Surface Area | 76.7 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 573 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ziprasidone hydrochloride |
Drug Label | GEODON is available as capsules (ziprasidone hydrochloride) for oral administration and as an injection (ziprasidone mesylate) for intramuscular use only. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophen... |
Active Ingredient | Ziprasidone hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 20mg base; eq 40mg base; eq 80mg base; eq 60mg base |
Market Status | Prescription |
Company | Mylan Pharms; Wockhardt; Apotex; Lupin Pharms; Sandoz; Dr Reddys Labs |
2 of 2 | |
---|---|
Drug Name | Ziprasidone hydrochloride |
Drug Label | GEODON is available as capsules (ziprasidone hydrochloride) for oral administration and as an injection (ziprasidone mesylate) for intramuscular use only. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophen... |
Active Ingredient | Ziprasidone hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 20mg base; eq 40mg base; eq 80mg base; eq 60mg base |
Market Status | Prescription |
Company | Mylan Pharms; Wockhardt; Apotex; Lupin Pharms; Sandoz; Dr Reddys Labs |
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17922
Submission : 2004-12-23
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-11-30
Written Confirmation Number : WC-390A4
Address of the Firm :
NDC Package Code : 55111-801
Start Marketing Date : 2004-12-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21147
Submission : 2007-12-17
Status : Active
Type : II
Date of Issue : 2022-06-06
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039
Address of the Firm :
NDC Package Code : 55111-801
Start Marketing Date : 2004-12-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19503
Submission : 2006-05-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-02-27
Pay. Date : 2016-12-27
DMF Number : 31183
Submission : 2016-12-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18042
Submission : 2005-01-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24837
Submission : 2011-03-31
Status : Inactive
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21147
Submission : 2007-12-17
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17922
Submission : 2004-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19005
Submission : 2005-12-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20105
Submission : 2006-12-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18050
Submission : 2005-02-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21012
Submission : 2007-10-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18055
Submission : 2005-02-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18042
Submission : 2005-01-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19503
Submission : 2006-05-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-07
Pay. Date : 2014-04-04
DMF Number : 20769
Submission : 2007-08-10
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Exclusivity Code : M-232
Exclusivity Expiration Date : 2025-01-28
Application Number : 20825
Product Number : 1
Exclusivity Details :
Exclusivity Code : M-232
Exclusivity Expiration Date : 2025-01-28
Application Number : 20825
Product Number : 2
Exclusivity Details :
Exclusivity Code : M-232
Exclusivity Expiration Date : 2025-01-28
Application Number : 20825
Product Number : 3
Exclusivity Details :
Exclusivity Code : M-232
Exclusivity Expiration Date : 2025-01-28
Application Number : 20825
Product Number : 4
Exclusivity Details :
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?